Using iridium complexes to activate carbon-hydrogen bonds for new drug synthesis
Iridium complexes for the activation and functionalization of carbon hydrogen-bonds in unactivated substrates
This study is looking at new ways to help create complex organic compounds from simple ones, which could lead to making new medicines and important chemicals that are hard to produce right now.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11065465 on NIH RePORTER |
What this research studies
This research focuses on developing new methods to activate carbon-hydrogen bonds in simple organic molecules, which can lead to the creation of complex organic compounds. By utilizing iridium-catalyzed reactions with specially designed ligands, the project aims to improve the efficiency and selectivity of these chemical processes. This could enable the synthesis of new drug candidates and biologically relevant compounds that were previously difficult to produce. The research will also explore additional applications in chemical reactions that are currently underdeveloped.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research would be individuals with conditions that could be treated by new drug candidates developed through these innovative synthetic methods.
Not a fit: Patients who are not seeking new treatment options or those with conditions that do not require complex organic compounds may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new medications and therapies by enabling the synthesis of complex organic molecules more efficiently.
How similar studies have performed: Other research has shown success with similar catalytic approaches in organic synthesis, indicating a promising avenue for developing new therapeutic agents.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Schley, Nathan David — Vanderbilt University
- Study coordinator: Schley, Nathan David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.